Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499793 | 1.00 | TSHR (0.64) | TSHRALDH1A1TRPA1FAAHTRPV1 | |
| SCHEMBL9140978 | 1.00 | TSHR (0.64) | TSHRALDH1A1TRPA1FAAHTRPV1 | |
| SCHEMBL9142236 | 1.00 | TSHR (0.64) | TSHRALDH1A1TRPA1FAAHTRPV1 | |
| SCHEMBL9142379 | 1.00 | TSHR (0.64) | TSHRALDH1A1TRPA1FAAHTRPV1 | |
| SCHEMBL9141366 | 1.00 | TSHR (0.64) | TSHRALDH1A1TRPA1FAAHTRPV1 | |
| SCHEMBL8854231 | 0.90 | TSHR (0.54) | TSHRALDH1A1TRPA1 | |
| SCHEMBL23647759 | 0.89 | TSHR (0.44) | TSHRFAAHTRPV1 | |
| SCHEMBL887761 | 0.89 | TSHR (0.44) | TSHRFAAHTRPV1 | |
| SCHEMBL7527108 | 0.89 | TSHR (0.44) | TSHRFAAHTRPV1 | |
| SCHEMBL1279585 | 0.89 | TSHR (0.44) | TSHRFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0282127-B1 | Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them | PROCTER & GAMBLE (US) | 1994-02-02 | — | — | EP | claimed |
| US-5099030-A | Phenols or phenolic ethers | THE PROCTER & GAMBLE COMPANY (US) | 1992-03-24 | — | — | US | claimed |
| US-5045565-A | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain | THE PROCTER & GAMBLE COMPANY (US) | 1991-09-03 | — | — | US | claimed |
| EP-0282127-A2 | Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them | THE PROCTER & GAMBLE COMPANY (US) | 1988-09-14 | — | — | EP | claimed |
| US-8207376-B2 | Method for producing amino acid phosphates | COSMO OIL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090281347-A1 | METHOD FOR PRODUCING AMINO ACID PHOSPHATES | COSMO OIL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2006279-A1 | METHOD FOR PRODUCTION OF PHOSPHATE SALT OF AMINO ACID | COSMO OIL CO., LTD. (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-6858226-B2 | Fusogenic lipids and vesicles | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030082154-A1 | Fusogenic lipids and vesicles | ISIS PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| US-5461075-A | Use of vanilloids for the prevention of lesions due to herpes simplex infections | THE PROCTER & GAMBLE COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0347000-B1 | The use of vanilloids for the manufacture of a medicament for treating herpes simplex infections | PROCTER & GAMBLE (US) | 1994-10-26 | — | — | EP | disclosed |
| EP-0282127-B1 | Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them | PROCTER & GAMBLE (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5099030-A | Phenols or phenolic ethers | THE PROCTER & GAMBLE COMPANY (US) | 1992-03-24 | — | — | US | disclosed |
| US-5045565-A | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain | THE PROCTER & GAMBLE COMPANY (US) | 1991-09-03 | — | — | US | disclosed |
| EP-0401903-A2 | The use of vanilloids for the treatment of respiratory diseases or disorders | THE PROCTER & GAMBLE COMPANY (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0347000-A2 | The use of vanilloids for the manufacture of a medicament for treating herpes simplex infections | THE PROCTER & GAMBLE COMPANY (US) | 1989-12-20 | — | — | EP | disclosed |
| EP-0282127-A2 | Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them | THE PROCTER & GAMBLE COMPANY (US) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082154-A1 | Fusogenic lipids and vesicles | NSF, CHMP4B, ABHD16A | TSHR 4354/4885ALDH1A1 4622/4885TRPA1 3421/4885 |
| US-20090281347-A1 | METHOD FOR PRODUCING AMINO ACID PHOSPHATES | AASDHPPT, NPEPPS, ALAD | TSHR 4141/4885ALDH1A1 4441/4885TRPA1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.